Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

772
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
772
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

295
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
295
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

903
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
903
Glaucoma: Overview01:25

Glaucoma: Overview

1.0K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.0K
Direct-Acting Cholinergic Agonists: Pharmacological Actions00:59

Direct-Acting Cholinergic Agonists: Pharmacological Actions

1.9K
Direct-acting cholinergic agonists exert their pharmacological actions by mimicking the effects of acetylcholine on postsynaptic muscarinic receptors to generate parasympathetic responses. These agents elicit a range of physiological responses, including cardiovascular effects. For example, activation of muscarinic receptors induces bradycardia, decreased cardiac output, reduced peripheral resistance, and consequent hypotension. In the eye, stimulation of M3 receptors leads to smooth muscle...
1.9K
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

1.2K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corneal Anterior and Posterior Changes in a Patient With Keratitis Associated With <i>Mycobacterium chelonae</i>: A Case Report.

Case reports in ophthalmological medicine·2026
Same author

Age-dependent association of the METTL23 c.84+60delAT variant with normal-tension glaucoma.

Journal of human genetics·2026
Same author

Rapid Epithelial Ingrowth Following Laser In Situ Keratomileusis due to Screwdriver Trauma.

Case reports in ophthalmological medicine·2026
Same author

Intrapapillary Damage and Its Functional Association in Normal Tension Glaucomatous Eyes With and Without Peripapillary Intrachoroidal Cavitation.

Investigative ophthalmology & visual science·2026
Same author

Optic nerve head abnormalities in primary open-angle glaucoma and their associations with axial length.

Japanese journal of ophthalmology·2026
Same author

Efficacy and Safety of Initial Outflow Reconstruction Using Ab Interno Microhook Trabeculotomy: A Retrospective Study in Secondary Glaucoma [Response to Letter].

Clinical ophthalmology (Auckland, N.Z.)·2026

Related Experiment Video

Updated: Oct 29, 2025

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

13.3K

Prostanoid receptor agonists for glaucoma treatment.

Makoto Aihara1

  • 1Department of Ophthalmology, University of Tokyo School of Medicine, 7-3-1 Hongo Bunkyo-ku, Tokyo, 113-8655, Japan. aihara-tky@umin.net.

Japanese Journal of Ophthalmology
|July 6, 2021
PubMed
Summary

Prostaglandin analogues and omidenepag effectively lower intraocular pressure for glaucoma. This review explores their history, efficacy, and distinct safety profiles, highlighting prostanoid receptor agonists

Keywords:
EP2 receptorFP receptorIntraocular pressureProstaglandinProstanoid

More Related Videos

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

1.6K
Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
06:19

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

1.1K

Related Experiment Videos

Last Updated: Oct 29, 2025

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

13.3K
Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

1.6K
Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
06:19

Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology

Published on: May 31, 2024

1.1K

Area of Science:

  • Ophthalmology
  • Pharmacology

Background:

  • Intraocular pressure (IOP) reduction is the cornerstone of glaucoma management.
  • Prostaglandin analogues (FP receptor agonists) have been first-line therapy for two decades due to high efficacy.
  • Omidenepag, an EP2 receptor agonist, represents a newer class of IOP-lowering agents.

Purpose of the Study:

  • To review the historical development and therapeutic potential of prostanoid FP and EP2 receptor agonists for glaucoma.
  • To compare the efficacy and safety profiles of these two classes of IOP-lowering drugs.
  • To elucidate the role of prostanoid receptor agonists in glaucoma treatment.

Main Methods:

  • Literature review of prostaglandin analogues (latanoprost, travoprost, bimatoprost, tafluprost) and omidenepag.
  • Analysis of studies on intraocular pressure reduction mechanisms via FP and EP2 receptors.
  • Comparison of clinical data on efficacy and safety profiles.

Main Results:

  • Both FP and EP2 receptor agonists demonstrate comparable IOP-lowering efficacy.
  • Significant differences exist in their safety profiles due to distinct intracellular signaling pathways.
  • Prostanoid receptor agonists offer substantial potential for glaucoma management.

Conclusions:

  • FP and EP2 receptor agonists are valuable therapeutic options for reducing intraocular pressure in glaucoma.
  • Understanding receptor-specific signaling is crucial for optimizing safety and efficacy.
  • Further research into prostanoid receptor modulation may yield improved first-line glaucoma treatments.